Literature DB >> 21744990

Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.

J Halamkova1, I Kiss, Z Pavlovsky, J Tomasek, J Jarkovsky, Z Cech, S Tucek, L Hanakova, M Moulis, J Zavrelova, M Man, P Benda, O Robek, Z Kala, M Penka.   

Abstract

Urokinase (uPA) plays an essential role in the activation of plasminogen to plasmin, and together with its receptor (uPAR), tissue activator (tPA) and urokinase inhibitors (PAI 1, PAI 2, PAI 3 and protease nexin) forms the plasminogen activator system (PAS), a component of metastatic cascade importantly contributing to the invasive growth and angiogenesis of malignant tumours. In our project we examined the expression of uPA, uPAR, PAI 1 and PAI 2 in tumor tissue and we also studied the plasma levels of PAI 1 before and after the initiation of therapy in patients with colorectal carcinoma in relationship to grade of tumor and the treatment response. In our prospective evaluation we included 80 patients treated for adenocarcinoma of the colon and rectum. Analysis of collected data revealed statistically significant evidence of a relationship between the level of PAI 1 in plasma before treatment and grade of the tumor, which increases with tumor grade (p=0.025). We demonstrated that there exists a statistically significant relationship between the expression of PAI 2 (p<0.001) and uPAR (p=0.031) and grade of tumor. We also confirmed a statistically significant relationship between soluble levels of PAI 1 before treatment and therapeutic response (p=0.021). In our group of patients the expression of uPA, uPAR, PAI 1 and 2 in tumor tissue in relation to response to treatment was also assessed. Our results suggest that the greater expression of these parameters in tumor tissue is linked to a worse response to therapy. In conclusion, PAS factors help as a prognostic indicators and could also act as a predictive factor in colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744990     DOI: 10.4149/neo_2011_05_377

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

1.  Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients.

Authors:  Yixin Xu; Can Cao; Ziyan Zhu; Yibo Wang; Yulin Tan; Xuezhong Xu
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

2.  A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.

Authors:  Toru Sasaki; Hirotaka Nishi; Chie Nagata; Takeshi Nagai; Toshitaka Nagao; Fumitoshi Terauchi; Keiichi Isaka
Journal:  Int J Clin Oncol       Date:  2014-01-30       Impact factor: 3.402

Review 3.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

4.  Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.

Authors:  Khaled Shahrour; Rick Keck; Jerzy Jankun
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

Review 5.  Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.

Authors:  Lianghua Fang; Qing Xu; Jun Qian; Jin-Yong Zhou
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

Review 6.  Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Authors:  Bing-Tao Zhai; Huan Tian; Jing Sun; Jun-Bo Zou; Xiao-Fei Zhang; Jiang-Xue Cheng; Ya-Jun Shi; Yu Fan; Dong-Yan Guo
Journal:  J Transl Med       Date:  2022-03-18       Impact factor: 5.531

7.  Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.

Authors:  Elisavet Karamanavi; Katerina Angelopoulou; Sophia Lavrentiadou; Anastasia Tsingotjidou; Zaphiris Abas; Ioannis Taitzoglou; Ioannis Vlemmas; Suzan E Erdman; Theofilos Poutahidis
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

Review 8.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.